Literature DB >> 19841145

In vivo activities of recombinant divercin V41 and its structural variants against Listeria monocytogenes.

Jitka Rihakova1, Jean-Michel Cappelier, Isabelle Hue, Katerina Demnerova, Michel Fédérighi, Hervé Prévost, Djamel Drider.   

Abstract

Recombinant divercin RV41 (DvnRV41) and its structural variants were used in this study to assess their antilisterial activities in vivo in mice challenged intravenously with Listeria monocytogenes EGDe. Treatment with DvnRV41 before and after infection permitted a conclusion as to the capacities of this peptide to retain activity and reduce growth of L. monocytogenes EGDe. Moreover, the use of structural variants for the first time in vivo and the reductions of their activities confirmed the importance of certain amino acids in antilisterial activity.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19841145      PMCID： PMC2798489          DOI： 10.1128/AAC.00765-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro.

Authors:  Mónica B Wachsman; Viviana Castilla; Aida P de Ruiz Holgado; Ramón A de Torres; Fernando Sesma; Celia E Coto
Journal:  Antiviral Res       Date:  2003-03       Impact factor: 5.970

2.  Evidence on inhibition of Listeria monocytogenes by divercin V41 action.

Authors:  C Richard; A Brillet; M F Pilet; H Prévost; D Drider
Journal:  Lett Appl Microbiol       Date:  2003       Impact factor: 2.858

3.  Comparative genomics of Listeria species.

Authors:  P Glaser; L Frangeul; C Buchrieser; C Rusniok; A Amend; F Baquero; P Berche; H Bloecker; P Brandt; T Chakraborty; A Charbit; F Chetouani; E Couvé; A de Daruvar; P Dehoux; E Domann; G Domínguez-Bernal; E Duchaud; L Durant; O Dussurget; K D Entian; H Fsihi; F García-del Portillo; P Garrido; L Gautier; W Goebel; N Gómez-López; T Hain; J Hauf; D Jackson; L M Jones; U Kaerst; J Kreft; M Kuhn; F Kunst; G Kurapkat; E Madueno; A Maitournam; J M Vicente; E Ng; H Nedjari; G Nordsiek; S Novella; B de Pablos; J C Pérez-Diaz; R Purcell; B Remmel; M Rose; T Schlueter; N Simoes; A Tierrez; J A Vázquez-Boland; H Voss; J Wehland; P Cossart
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

4.  Foodborne listeriosis.

Authors:  W F Schlech
Journal:  Clin Infect Dis       Date:  2000-09-26       Impact factor: 9.079

5.  The bacteriocin piscicolin 126 retains antilisterial activity in vivo.

Authors:  Aaron Ingham; Mark Ford; Robert J Moore; Mark Tizard
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

6.  A class IIa peptide from Enterococcus mundtii inhibits bacteria associated with otitis media.

Authors:  H Knoetze; S D Todorov; L M T Dicks
Journal:  Int J Antimicrob Agents       Date:  2007-12-26       Impact factor: 5.283

7.  Heterologous expression and purification of active divercin V41, a class IIa bacteriocin encoded by a synthetic gene in Escherichia coli.

Authors:  Christelle Richard; Djamel Drider; Khalil Elmorjani; Didier Marion; Hervé Prévost
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

8.  Identification of new genes associated with intermediate resistance of Enterococcus faecalis to divercin V41, a pediocin-like bacteriocin.

Authors:  Ségolène Calvez; Alain Rincé; Yanick Auffray; Hervé Prévost; Djamel Drider
Journal:  Microbiology       Date:  2007-05       Impact factor: 2.777

9.  Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus.

Authors:  M De Kwaadsteniet; K T Doeschate; L M T Dicks
Journal:  Lett Appl Microbiol       Date:  2008-11-14       Impact factor: 2.858

10.  Bacteriocin ST91KM, produced by Streptococcus gallolyticus subsp. macedonicus ST91KM, is a narrow-spectrum peptide active against bacteria associated with mastitis in dairy cattle.

Authors:  Reneé Pieterse; Svetoslav D Todorov; Leon M T Dicks
Journal:  Can J Microbiol       Date:  2008-07       Impact factor: 2.419
View more
  9 in total

1.  Physiological and Structural Differences Between Enterococcus faecalis JH2-2 and Mutant Strains Resistant to (P)-Divercin RV41.

Authors:  S Calvez; A Kohler; H Prévost; T Møretrø; D Drider
Journal:  Probiotics Antimicrob Proteins       Date:  2010-12       Impact factor: 4.609

2.  Effect of recombinant divercin RV41, structural variants and the activators of potassium channels on Listeria monocytogenes EGDe.

Authors:  J Rihakova; H Prevost; K Demnerova; D Drider
Journal:  Folia Microbiol (Praha)       Date:  2011-04-06       Impact factor: 2.099

Review 3.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

Review 4.  Biochemical Features of Beneficial Microbes: Foundations for Therapeutic Microbiology.

Authors:  Melinda A Engevik; James Versalovic
Journal:  Microbiol Spectr       Date:  2017-10

Review 5.  Lactic Acid Bacteria (LAB) and Their Bacteriocins as Alternative Biotechnological Tools to Control Listeria monocytogenes Biofilms in Food Processing Facilities.

Authors:  Anderson C Camargo; Svetoslav D Todorov; N E Chihib; D Drider; Luís A Nero
Journal:  Mol Biotechnol       Date:  2018-09       Impact factor: 2.695

6.  Development of Class IIa Bacteriocins as Therapeutic Agents.

Authors:  Christopher T Lohans; John C Vederas
Journal:  Int J Microbiol       Date:  2011-11-30

7.  Sil: a Streptococcus iniae bacteriocin with dual role as an antimicrobial and an immunomodulator that inhibits innate immune response and promotes S. iniae infection.

Authors:  Mo-fei Li; Bao-cun Zhang; Jun Li; Li Sun
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

Review 8.  A Review: The Fate of Bacteriocins in the Human Gastro-Intestinal Tract: Do They Cross the Gut-Blood Barrier?

Authors:  Leon M T Dicks; Leané Dreyer; Carine Smith; Anton D van Staden
Journal:  Front Microbiol       Date:  2018-09-28       Impact factor: 5.640

9.  Emerging Applications of Bacteriocins as Antimicrobials, Anticancer Drugs, and Modulators of The Gastrointestinal Microbiota.

Authors:  Catherine Cesa-Luna; Julia-María Alatorre-Cruz; Ricardo Carreño-López; Verónica Quintero-Hernández; Antonino Baez
Journal:  Pol J Microbiol       Date:  2021-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.